Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background. Diabetes mellitus and its complications are a public health problem of epidemic proportions. Both diabetes and chronic kidney disease (CKD) increase the risk of acute kidney injury (AKI). Months after a single episode of acute ischaemia to the diabetic kidney, we have found an accelerated progression of nephropathy, with impaired function, severe renal inflammation, microvascular dysfunction, fibrosis and apoptotic cell death. We termed this entity the post-ischaemic inflammatory syndrome. We now test the hypothesis that blocking inflammation ameliorates the post-ischaemic inflammatory syndrome.Methods. Obese-diabetic ZS rats (F1 hybrids of spontaneously hypertensive heart failure and Zucker fatty diabetic rats) were treated with mycophenolate mofetil (MMF), subjected to renal ischaemia or sham surgery, and monitored via the powerful technique of intravital microscopy. Results. Amelioration of post-ischaemia inflammation with MMF therapy improved long-term renal function, microvascular dysfunction, fibrosis and apoptosis.Conclusion. These data support the hypothesis that the post-ischaemic inflammatory syndrome accelerates diabetic CKD, is a critical determinant of injury, and can be successfully treated.

Original languageEnglish (US)
Pages (from-to)3204-3212
Number of pages9
JournalNephrology Dialysis Transplantation
Issue number10
StatePublished - Oct 2010


  • acute kidney failure
  • anti-inflammatory agents
  • diabetic nephropathies
  • inflammation
  • ischaemia

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy'. Together they form a unique fingerprint.

Cite this